FDA Accepts Immunome's NDA for Varegacestat in Desmoid Tumors — Immunome, Inc.

Event summary

Immunome's NDA for varegacestat in desmoid tumors accepted by the FDA with a PDUFA target action date of April 28, 2027.
Phase 3 RINGSIDE trial met primary endpoint, showing an 84% reduction in disease progression risk vs. placebo (HR=0.16, p<0.0001).
Key secondary endpoints also met: 56% objective response rate vs. 9% with placebo and significant pain reduction at week 12.
Varegacestat demonstrated a median best change in tumor volume of -83% vs. +11% with placebo.

The big picture

Immunome's NDA acceptance marks a critical step in addressing desmoid tumors, a rare but debilitating condition with limited systemic treatment options. The robust Phase 3 data positions varegacestat as a potential first-in-class oral therapy, aligning with broader industry trends toward targeted oncology treatments. Success here could validate Immunome’s strategy of developing differentiated cancer therapies.

What we're watching

Regulatory Review: Whether the FDA will approve varegacestat by the April 28, 2027 PDUFA date.
Commercialization Strategy: How Immunome plans to position varegacestat in a niche oncology market with limited treatment options.
Pipeline Progress: The pace at which Immunome advances its broader portfolio of targeted cancer therapies, including IM-1021 and IM-3050.